Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DSGN vs PVLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PVLA Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 2–3 Matrix Metrics)
PVLA Overall Winner
6-Pillar Tally: DSGN 1 – 2 PVLA (3 Tie)
Matrix Metrics: DSGN 3 – 2 PVLA
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (2–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
- Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DSGN vs PVLA
DSGN
Design Therapeutics, Inc. Common Stock
$9.94
-5.06% 1D
Market Cap
$677.5M
TTM Revenue
$33,000
Forward P/E
N/M
Beta / 30D Vol
1.32β · 61% Vol
Unified Composite Score
49.9
HOLD
Tech 55.0
Fund 56.0
Flow 63.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
PVLA
Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
$145.03
-4.89% 1D
Market Cap
$2.2B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.66β · 75% Vol
Unified Composite Score
48.2
HOLD
Tech 35.0
Fund 53.0
Flow 67.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (DSGN 1 – 2 PVLA)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
Tie
Revenue Growth (YoY)
+0.0%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$33,000
N/A
Market Cap
$677.5M
$2.2B
3. Profitability & Quality
DSGN
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-36.9%
-63.4%
4. Balance Sheet & Cash Flow
PVLA
Cash Generation (TTM)
-$59M
-$43M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$13M Net Cash
$193M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PVLA
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
92.0% (13th %ile)
47.9% (2nd %ile)
Put/Call OI Skew
N/A
3.82x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DSGN (3) vs PVLA (2)| Institutional Metric | DSGN | PVLA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $677.5M | $2.2B | PVLA | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +0.0% | Tie | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -36.9% | -63.4% | DSGN | |
| 52-Week Range Position | 30% ($7–$17) | 68% ($72–$180) | PVLA | |
| Beta / 30D Volatility | 1.32β · 61% Vol | 1.66β · 75% Vol | DSGN | |
| Unified Institutional Score | 49.9 / 100 (HOLD) | 48.2 / 100 (HOLD) | DSGN | |
| Trailing 12M Revenue (USD) | $33,000 | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$59M ($13M Net Cash) | -$43M ($193M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PVLA +24.15 pp
3M Horizon
PVLA +31.33 pp
6M Horizon
PVLA +45.16 pp
1Y Horizon
PVLA +39.37 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DSGN Revenue | PVLA Revenue | DSGN Op. Margin | PVLA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2016 | N/A | $10M | N/A | -390.3% | PVLA |
| FY2017 | N/A | $30M | N/A | -57.7% | PVLA |
| FY2018 | N/A | $30M | N/A | -113.1% | PVLA |
| FY2019 | N/A | $40M | N/A | -62.2% | PVLA |
| FY2020 | $0M | $30M | -3685.8% | -115.7% | PVLA |
| FY2021 | N/A | $30M | N/A | -165.0% | PVLA |
| FY2022 | N/A | $30M | N/A | -167.8% | PVLA |
| FY2023 | N/A | $40M | N/A | -27.7% | PVLA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DSGN
BREAKDOWN
Current IV
92.0%
IV Percentile
13th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PVLA
CONSOLIDATION
Current IV
47.9%
IV Percentile
2nd %ile
Put/Call OI Skew
3.82x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DSGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PVLA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DSGN vs PVLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (2–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DSGN and PVLA split Growth & Scale metrics: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2016 to FY2023), DSGN cumulative revenue shifted N/A while PVLA shifted +300.0%. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.
DSGN and PVLA trade at balanced relative valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus PVLA (-63.4% ROE) capital efficiency.
In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PVLA vs DSGN · Reverse Pair
DSGN vs CGEM
· Sector Peer
DSGN vs EWTX
· Sector Peer
DSGN vs IMCR
· Sector Peer
PVLA vs ORKA
· Sector Peer
PVLA vs DNTH
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem